A Phase 1 Trial of LIB-01 in Healthy Participants.
Status:
COMPLETED
Trial end date:
2024-05-29
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are:
* How safe and tolerable is LIB-01 when given once or repeatedly at different dose levels.
* What are the pharmacokinetic characteristics of LIB-01
Participants will receive LIB-01 and be followed up for safety and pharmacokinetics by:
* Adverse events
* ECG
* Blood sampling for laboratory parameters and pharmacokinetic analysis